SCHEMBL30482353

SCHEMBL30482353

Cn1c(=O)n(Cc2ccccc2C(F)(F)F)c(=O)c2c(N)ccc(F)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GNRHR P30968 2/20 0.43
▸ PARG Q86W56 2/20 0.42
▸ TSHR P16473 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ C5AR1 P21730 4/20 0.38
▸ ADORA2A P29274 2/20 0.38
▸ HSD17B13 Q7Z5P4 2/20 0.38
▸ SLC16A1 P53985 2/20 0.38
▸ CMA1 P23946 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227182 0.87 TSHR (0.41) GNRHRPARGTSHRALDH1A1NPC1
SCHEMBL26230397 0.78 HSD17B13 (0.45) GNRHRPARGLMNAHSD17B13CMA1
SCHEMBL30482332 0.76 TDP1 (0.45) GNRHRTDP1C5AR1
SCHEMBL30482379 0.76 HSD17B13 (0.39) GNRHRPARGTDP1HSD17B13CMA1
SCHEMBL30482352 0.72 TSHR (0.55) PARGTSHRALDH1A1NPC1KDM4E
SCHEMBL25433299 0.72 HSD17B13 (0.74) HSD17B13
SCHEMBL30482276 0.72 HSD17B13 (0.74) HSD17B13
SCHEMBL31227425 0.70 HPGD (0.43) TSHRTDP1HSD17B13MEN1HPGD
SCHEMBL31227306 0.65 ADORA2A (0.45) GNRHRALDH1A1KDM4ETDP1C5AR1
SCHEMBL31227314 0.65 TDP1 (0.45) GNRHRTDP1C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2025-03-27 — — US disclosed
EP-4469451-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-12-04 — — EP disclosed
CN-119032090-A 2-Substituted thiazole HSD17B13 inhibitors and uses thereof 伊尼制药公司 2024-11-26 — — CN disclosed
WO-2023146897-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 GNRHR 4149/4885PARG 4538/4885TSHR 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback